Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A diagram showing the plan of visits for the DC-MACS study

STUDY OVERVIEW

Mild autonomous cortisol secretion (MACS) is a condition where benign adrenal tumours produce excess cortisol, a ‘stress hormone’. This affects about 300,000 people aged over 70 years in the UK, leading to medical problems such as diabetes, poor bone health, and heart disease. Currently, there are no approved treatments for MACS.

DC-MACS will investigate the efficacy of SPI-62, a drug hypothesised to improve the signs of MACS, and the adverse effects associated with prescribed corticosteroids by stopping the body’s ability of making even more cortisol in peripheral tissues.

STUDY DESIGN

This is a randomised, double-blind, placebo-controlled trial, which will involve 40 participants, each participating for a total duration of 20 weeks, including pre-treatment, treatment and follow-up periods. The study is structured into 5 to 7 participant visits and 2 follow-up telephone calls. The treatment phase spans 12 weeks, and involves taking 6 mg study tablet per day.  Assessments occur at: baseline, week 4, week 8, and week 12.

All trial activities will be performed at the OCDEM clinical research unit (CRU) based at the Churchill hospital and at Sheffield Teaching Hospital.

AIMS

Primary

To determine if SPI-62 compared to placebo can improve glucose metabolism in people with MACS 

Secondary

To investigate if SPI-62 improves bone health, brain function, quality of life, blood pressure, liver health, body composition, cholesterol levels, and steroid levels compared to a placebo in people with MACS. In addition, the trial will determine the safety tolerability of SPI-62. 

STUDY TEAM

Chief Investigator: Jeremy Tomlinson

Co-Investigators: John Newell-Price, Amanda Adler, Leanne Hodson

Trial Manager: Nkemjika Abiakam 

Email: dc-macs@dtu.ox.ac.uk

Tel: +44 (0)1865857244

SPONSOR & FUNDER

Sponsor: University of Oxford

Funder: Medical Research Council

INFORMATION FOR PARTICIPANTS

Download Participant Information Sheet (PIS)

CONTACT US

For more information: 
dcmacstrial2024@ocdem.ox.ac.uk

About Diabetes

Find out about diabetes, key facts and figures, and how it is currently treated.

About Clinical Research

Find out more about what researchers do and how trials are carried out.

Get Involved

Find out how to take part in our studies.